Article Information
History
- July 19, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jorge Camacho, b Pharm1,†,
- Estela Giménez, PhD1,†,
- Eliseo Albert, PhD1,
- Joao Zulaica, PhD2,
- Beatriz Álvarez-Rodríguez, PhD2,
- Ignacio Torres, PhD1,
- Luciana Rusu, PhD2,
- Javier S. Burgos, MD3,
- Salvador Peiró, MD4,
- Hermelinda Vanaclocha, MD5,
- Ramón Limón, MD6,
- María Jesús Alcaraz, MD1,
- José Sánchez-Payá, MD7,8,
- Javier Díez-Domingo, MD4,
- Iñaki Comas, PhD9,10,
- Fernando Gonzáles-Candelas, PhD2,10,
- Ron Geller, PhD2,
- David Navarro, MD1,11,* and
- the Valencian Vaccine Research Program (ProVaVac) study group
- 1Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
- 2Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980, Valencia, Spain
- 3General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain
- 4Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain
- 5General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain
- 6General Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain
- 7Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain
- 8Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain
- 9Biomedicine Institute of Valencia, Spanish Research Council (CSIC)
- 10CIBER in Epidemiology and Public Health, Spain; Joint Research Unit “Infection and Public Health” FISABIO-University of Valencia, Valencia, Spain
- 11Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
- ↵*Correspondence:
David Navarro, Microbiology Service, Hospital Clínico Universitario, Instituto de Investigación INCLIVA. Av. Blasco Ibáñez 17, 46010 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; Email: david.navarro{at}uv.es.
- 13Vice-President Foundation Research Institute in Public Services, Valencia, Spain
- 15The Prince Felipe Research Center-CIPF-, Valencia, Spain
- 16INCLIVA Health Research Institute, Valencia, Spain
- 18Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain
- 20CIBER in Epidemiology and Public Health, Spain
- 21Joint Research Unit “Infection and Public Health” FISABIO-University of Valencia, Valencia, Spain
- 22Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain
- 23Fundación Hospital Provincial de Castelló
- 28Instituto de Investigación Sanitaria La Fe
- 29Biotechnology Department, University of Alicante, Spain
- 30Fundación Hospital General Universitario de València
↵† Both authors contributed equally to the current work.
Posted July 19, 2022.
Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant
